AI could spot hidden prostate cancers missed by standard biopsies

NCT ID NCT07231627

Recruiting now Diagnosis Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an artificial intelligence (AI) algorithm can help doctors decide where to take biopsy samples in men with prostate MRI findings that are not clearly cancerous. About 50 men with low-risk or uncertain MRI lesions and elevated PSA levels will be randomly assigned to either AI-guided biopsy or standard biopsy. The goal is to see if the AI approach finds more clinically significant prostate cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence algorithm for biopsy guidance
What this could lead to: If successful, this AI approach could help doctors find more aggressive prostate cancers while reducing unnecessary biopsies.
What could go wrong: This is an early-phase study with only 50 participants, so results may not apply to all patients. The AI might not perform better than standard methods in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University of Arkansas for Medical Sciences
RECRUITING

Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.